EyePoint Inc (EYPT) Unusual Options Activity Today

Checking EYPT unusual options activity helps you spot when traders are making outsized bets on EyePoint Inc before the broader market catches on. EyePoint Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor EYPT unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching EYPT unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking EYPT unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and EYPT unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.

It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Catalysts rarely arrive without a footprint, and EYPT unusual options activity is often where that footprint shows up first. Our scanner tracks EyePoint Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at EYPT unusual options volume on the call side or chasing put sweeps, EyePoint Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.